A daily targeted pill for soft-tissue sarcoma, taken on an empty stomach. The most important monitoring is for liver injury (frequent blood tests, especially early) — it carries a boxed warning. Blood pressure often rises in the first weeks, and tiredness and diarrhea are common. A harmless quirk: hair often turns lighter or grey.
Oral pazopanib taken once daily on an empty stomach, continuously (a VEGFR-targeted pill). It carries a BOXED WARNING for liver injury, so liver tests are checked frequently, especially in the first ~4 months. Blood pressure often rises early. A harmless but striking effect is HAIR turning lighter/grey. Onset is measured in weeks-months, not infusion cycles.
Get help straight away — this is true on any regimen, on any day.
A temperature of 100.4°F (38°C) or higher during treatment can mean a
serious infection while your blood counts are low. Call your team or go to the ER — do not
wait it out.
Also urgent: trouble breathing or chest pain · swelling of the face, lips or throat ·
new confusion or fainting · shaking chills · not being able to keep fluids down.
This is standing guidance shown to everyone. Nothing on this page is based on anything
about you, and nobody is monitoring you.
What is reported
This regimen is taken continuously, so effects are described in the terms their sources use rather than by cycle day.
Liver injury (hepatotoxicity) — boxed warning
often first ~18 weeks; any time
Pazopanib can raise liver blood tests and, uncommonly, cause serious (rarely fatal) liver injury — most often in the first ~4 months. This is why your team checks liver tests frequently early on (often weekly for a while) and adjusts or stops the drug if levels rise. Report yellowing of skin/eyes, dark urine, or belly pain.
Call your team urgently: Yellowing of skin/eyes, dark urine, or severe belly pain.
reported by about 46% (ALT rise) of people; severe in 10% · from Pazopanib
High blood pressure (hypertension)
early — many by ~day 9; ongoing
Blood pressure commonly rises early — often within the first week or two. Your team checks it frequently at the start and treats it with medicine; controlling it lets you stay on treatment.
Call your team: Severe headache, vision changes, or chest pain.
reported by about 41% of people; severe in 7% · from Pazopanib
Fatigue
Tiredness is very common and can persist while on treatment. Pace activities and rest.
reported by about 65% of people; severe in 13% · from Pazopanib
Diarrhea
Loose or frequent stools are common. Hydration and anti-diarrheal medicine as advised help.
reported by about 58% of people; severe in 5% · from Pazopanib
Decreased appetite / weight loss
Reduced appetite and weight loss are common. Small frequent high-calorie meals and dietitian support help; report rapid weight loss.
reported by about 40 (appetite); 48 (weight loss)% of people · from Pazopanib
Hair color change (lightening/greying)
over weeks-months; reverses off-drug
A striking but harmless effect: hair often turns lighter or grey over weeks-months (from the drug's effect on pigment). It reverses after stopping the drug — no action needed.
reported by about 38% of people · from Pazopanib
Low thyroid / proteinuria / QT
weeks-months
Pazopanib can lower thyroid function (tiredness, cold), leak protein into the urine, and affect the heart's electrical timing (QT). These are usually found on monitoring; your team checks thyroid tests, urine protein, ECG, and blood salts.
reported by about 5 (hypothyroid); QT ≥500ms ~2%% of people · from Pazopanib
Where this comes from
S1. van der Graaf WTA, PALETTE (pazopanib, soft-tissue sarcoma, n=239) (2012) — PMID 22595799
S2. Pazopanib (Votrient) FDA prescribing information (boxed: hepatotoxicity) — FDA label
A window appears here only where a retrievable document ties it to a drug in
this regimen. Where nothing could be found, the window was removed rather than estimated —
so a missing time is an honest gap, not an oversight.